Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200862 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
A Phase 2 study, sponsored by Mereo BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01200862: Clinical Trial Phase 2 study, sponsored by Mereo BioPharma.
NCT01200862 is a Phase 2 study that was terminated before completion, run by Mereo BioPharma. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01200862, a Phase 2 study, was terminated before completion, sponsored by Mereo BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study is designed as a 2-part study, with Part 1 being open-label to best determine the appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo controlled design. The study aims to assess the safety and tolerability of BGS649, and determine whether or not BGS649 is able to normalize testosterone levels and improve insulin sensitivity in obese, hypogonadotropic hypogonadal (OHH) men
Primary Outcome
Percentage of patients achieving normal testosterone (2.50 - 9.50 ng/mL) levels at Week 4 and Week 12
Interventions
- DRUG Placebo
- DRUG Investigational new drug company code: BGS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Why NCT01200862 stopped before completion
NCT01200862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01200862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01200862 about?
NCT01200862 is a clinical study titled "Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men". This study is designed as a 2-part study, with Part 1 being open-label to best determine the appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo controlled design. The study aims to assess the safety and tolerability of BGS649, and determine whether or not BGS649 ...
What is the current status of trial NCT01200862?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2010-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01200862?
The interventions under investigation include: Placebo (DRUG), Investigational new drug company code: BGS649 (DRUG).
Who is sponsoring clinical trial NCT01200862?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01200862's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia